Seven Grand Managers LLC purchased a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 100,000 shares of the company’s stock, valued at approximately $3,276,000.
Other institutional investors also recently added to or reduced their stakes in the company. HighVista Strategies LLC increased its position in Spyre Therapeutics by 91.3% during the third quarter. HighVista Strategies LLC now owns 215,746 shares of the company’s stock worth $3,616,000 after buying an additional 102,941 shares during the period. Candriam S.C.A. increased its position in Spyre Therapeutics by 64.4% during the third quarter. Candriam S.C.A. now owns 404,362 shares of the company’s stock worth $6,777,000 after buying an additional 158,332 shares during the period. JPMorgan Chase & Co. increased its position in Spyre Therapeutics by 483.7% during the third quarter. JPMorgan Chase & Co. now owns 275,984 shares of the company’s stock worth $4,625,000 after buying an additional 228,705 shares during the period. Baker BROS. Advisors LP increased its position in Spyre Therapeutics by 59.6% during the third quarter. Baker BROS. Advisors LP now owns 1,000,000 shares of the company’s stock worth $16,760,000 after buying an additional 373,297 shares during the period. Finally, AlphaQuest LLC increased its position in Spyre Therapeutics by 1,485.1% during the third quarter. AlphaQuest LLC now owns 66,163 shares of the company’s stock worth $1,109,000 after buying an additional 61,989 shares during the period. Institutional investors and hedge funds own 80.39% of the company’s stock.
Insider Buying and Selling
In other news, CFO Scott L. Burrows sold 12,500 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $71.37, for a total value of $892,125.00. Following the transaction, the chief financial officer owned 97,994 shares of the company’s stock, valued at approximately $6,993,831.78. The trade was a 11.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sheldon Sloan sold 78,333 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $71.50, for a total value of $5,600,809.50. Following the completion of the transaction, the insider directly owned 78,333 shares in the company, valued at approximately $5,600,809.50. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 233,791 shares of company stock worth $15,757,860. 15.69% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on SYRE
Spyre Therapeutics Trading Down 1.5%
NASDAQ:SYRE opened at $72.51 on Thursday. The firm has a market cap of $6.30 billion, a P/E ratio of -34.86 and a beta of 3.12. The stock’s 50 day simple moving average is $62.43 and its 200-day simple moving average is $43.61. Spyre Therapeutics, Inc. has a 12-month low of $13.93 and a 12-month high of $78.80.
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.08). Research analysts forecast that Spyre Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.
Spyre Therapeutics Company Profile
Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.
Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.
Featured Stories
- Five stocks we like better than Spyre Therapeutics
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Want to see what other hedge funds are holding SYRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report).
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
